SCHEMBL1611952

SCHEMBL1611952

O=C1Nc2ccccc2C1(O)c1cc2c(cc1O)OCCO2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.63
MEN1 O00255 4/20 0.60
POLB P06746 2/20 0.43
CASP6 P55212 1/20 0.43
GAA P10253 1/20 0.41
MAPK1 P28482 1/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MTOR P42345 1/20 0.39
RICTOR Q6R327 1/20 0.39
RPTOR Q8N122 1/20 0.39
MAPKAP1 Q9BPZ7 1/20 0.39
MLST8 Q9BVC4 1/20 0.39
XBP1 P17861 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CHRM2 P08172 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
KCNH2 Q12809 1/20 0.38
IDO1 P14902 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1612096 0.92 KMT2A (0.63) KMT2AMEN1POLBCASP6GAA
SCHEMBL17244108 0.83 KMT2A (0.45) KMT2AMEN1POLBGAAMAPK1
SCHEMBL384666 0.75 KMT2A (0.43) KMT2AMEN1GAAMAPK1MAPT
SCHEMBL281811 0.74 KMT2A (0.42) KMT2AMEN1MTORRICTORRPTOR
SCHEMBL281520 0.73 KMT2A (0.69) KMT2AMEN1POLBCASP6GAA
SCHEMBL4597267 0.73 POLB (0.55) KMT2AMEN1POLBCASP6MTOR
SCHEMBL4732189 0.73 MTOR (0.44) KMT2AMEN1POLBGAAMAPK1
SCHEMBL15314988 0.73 TSHR (0.47) GAALMNAMAPTALDH1A1SCN9A
SCHEMBL2306814 0.72 KMT2A (0.40) KMT2AMEN1LMNAMTORRICTOR
SCHEMBL281976 0.72 KMT2A (0.40) KMT2AMEN1MTORRICTORRPTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9695185-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2017-07-04 US disclosed
US-9695185-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2017-07-04 US disclosed
US-9695185-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2017-07-04 US disclosed
US-20160326184-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2016-11-10 US disclosed
US-20160326184-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2016-11-10 US disclosed
US-20160326184-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2016-11-10 US disclosed
US-9260446-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2016-02-16 US disclosed
US-20140336390-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2014-11-13 US disclosed
US-20140336390-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2014-11-13 US disclosed
US-20140336390-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2014-11-13 US disclosed
US-8445696-B2 Synthetic methods for spiro-oxindole compounds XENON PHARMACEUTICALS INC. (CA) 2013-05-21 US disclosed
US-20130072686-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2013-03-21 US disclosed
US-20130072686-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2013-03-21 US disclosed
US-20130072686-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2013-03-21 US disclosed
EP-2488531-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS Xenon Pharmaceuticals Inc. (CA) 2012-08-22 EP disclosed
WO-2011047174-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-04-21 WO disclosed
WO-2011047174-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-04-21 WO disclosed
US-20110087027-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-04-14 US disclosed
US-20110087027-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-04-14 US disclosed
US-20110087027-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2011-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110087027-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS TRPV1, TRPV5, TRPV3 KMT2A 3185/4885MEN1 2759/4885POLB 4753/4885
US-20130072686-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS TRPV1, TRPV5, TRPV3 KMT2A 3185/4885MEN1 2759/4885POLB 4753/4885
US-20160326184-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS TRPV1, TRPV5, TRPV3 KMT2A 3185/4885MEN1 2759/4885POLB 4753/4885
US-20140336390-A1 SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS TRPV1, TRPV5, TRPV3 KMT2A 3185/4885MEN1 2759/4885POLB 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.